News

AbCheck licenses mAB technology
Enlarge image

BusinessCzech Republic

AbCheck licenses mAB technology

14.11.2012 - Plzen-based AbCheck s.r.o.has licensed an affinity maturation and antibody optimisation platform from US bioinformatics company Distributed Bio LCC.

Under the terms of the exclusive, worldwide agreement, AbCheck will apply Distributed Bio LCC’s proprietary computational library design algorithms to address the affinity maturation, therapeutic 'developability' and stability optimisation of antibodies in a one-step process.  According to the Czech antibody specialist, the platform of the US bioinformatics specialist makes it possible to deliver functional, "GMP ready", antibodies with significantly increased affinities with minimal mutations from fully human frameworks from its phage and yeast display antibody libraries

AbCheck CEO Volker Lang stressed: "By combining the strength of both technologies we have created a platform that exactly addresses current market needs.“ "Library design algorithms redefine the full potential of high throughput screening," said Jacob Glanville, Scientific Director of Distributed Bio. "Distributed Bio's library design algorithms encode years of protein engineering directly into the library designs. We are delighted to bring this technology forward with AbCheck: their leading edge expertise in antibody engineering and library development make them an ideal partner for introducing this new technology to the market.

Abcheck uses its AbSieve platform to develop antibodies for partners in all antibody formats, and its AbAccel algorithm for affinity maturation and optimisation. Distributed Bio provides antibody informatics, including: sequence & structural analysis; affinity maturation & humanisation; NextGen repertoire sequencing; phage display panning and library analysis.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/abcheck-licenses-antibody-technology.html

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

RegulationUKFranceGermanySpain

01.12.2014 In spite of innovative new medicines on the market, the UK and Germany lag behind other countries and continue to use older medicines - especially in the treatment of cancer. French and Spanish patients, on the other hand, benefit much earlier from medical innovation.

Events

All Events

Current issue

All issues

Product of the week

Products